Parathyroid hormone (PTH) treatment mainly treats hypoparathyroidism (too little parathyroid hormone). Symptoms can include tingling, muscle cramps, and in severe cases, seizures. Recombinant human ...

Parathyroid cancer is a very rare type of cancer that starts in the parathyroid gland. It can cause hyperparathyroidism, which can result in high calcium levels in the blood. The most common treatment ...

Applying a pretreatment of a parathyroid hormone, commonly used to increase bone mass to combat osteoporosis, can help improve cartilage health and slow the development of osteoarthritis, Cornell ...

Primary hyperparathyroidism in young patients is a rare endocrine disorder characterised by excessive secretion of parathyroid hormone from one or more glands. Affected children often present with non ...

Primary hyperparathyroidism occurs when the parathyroid glands produce too much parathyroid hormone (PTH). This can lead to health complications. Primary hyperparathyroidism is a relatively common ...

Secondary hyperparathyroidism is a complex endocrine condition characterized by excess circulating parathyroid hormone (PTH) resulting from an underlying condition, most commonly chronic kidney ...

While the approach to hypoparathyroidism (hypoPT) management is usually not fundamentally different in special populations (ie, it consists of conventional therapy supplemented or replaced with ...

A pair of clinical guidelines on hypo- and hyperparathyroidism, respectively, had a coming-out party at the American Society for Bone and Mineral Research's (ASBMR) annual meeting on Sunday, allowing ...

Pharmacological therapy for the management of hypoparathyroidism (hypoPT) can be supplemented by non-pharmacological intervention, primarily alterations to diet to increase intake of foods rich in ...

Excess parathyroid hormone due to over activity of parathyroid glands, four pea-sized glands located at the back of thyroid gland. Symptoms include loss of appetite, increased thirst and urination, ...

SINGAPORE, Feb. 20, 2025 /PRNewswire/ -- Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the registration of YORVIPATH® (palopegteriparatide) by the Therapeutic Goods ...